Share Price and Basic Stock Data
Last Updated: November 3, 2025, 10:03 pm
| PEG Ratio | -2.80 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
SMS Lifesciences India Ltd operates in the pharmaceutical sector, a space characterized by its potential for growth and innovation. The company reported sales of ₹335 Cr for the trailing twelve months (TTM), a notable recovery from the ₹316 Cr recorded in FY 2023. However, when we look back at the past few years, the revenue has shown fluctuations, with a peak of ₹378 Cr in FY 2019, followed by a dip to ₹261 Cr in FY 2020. The latest numbers indicate a gradual rebound, though they remain below the peak levels. Quarterly sales data shows mixed performance, with the most recent quarter (June 2025) achieving ₹82.50 Cr, which reflects a bounce-back from previous lows. This volatility in sales could be attributed to various factors, including market dynamics and the company’s operational strategies. Overall, while the revenue trends exhibit recovery, consistent growth remains a target for the company to ensure sustainable profitability.
Profitability and Efficiency Metrics
Profitability metrics for SMS Lifesciences reveal a complex picture. The company’s operating profit margin (OPM) stood at 14.19%, which is commendable compared to industry averages, suggesting efficient cost management. However, the road has not been entirely smooth; the OPM saw significant dips, particularly in March 2023, where it fell to a mere 3.58%. The latest financials indicate a recovery, with OPM rising to 14.19% in FY 2025. The net profit margin, however, has exhibited volatility, with a low of -3.83 Cr in June 2023 followed by improvements to ₹4.39 Cr in June 2025. Such fluctuations may raise eyebrows among investors, signaling potential operational challenges or market pressures. The interest coverage ratio of 5.73x is a positive indicator, highlighting the company’s ability to meet its interest obligations comfortably. Yet, the declining net profit margin from 7.23% in FY 2022 to 5.43% in FY 2025 suggests that while sales have improved, translating that into consistent bottom-line growth remains a work in progress.
Balance Sheet Strength and Financial Ratios
Turning to SMS Lifesciences’ balance sheet, the financial ratios present a picture of resilience amid challenges. The company reported total borrowings of ₹86 Cr against reserves of ₹194 Cr, indicating a manageable debt level relative to its equity. The debt-to-equity ratio of 0.42x suggests a conservative approach to leveraging, which is generally favorable for a company in the pharmaceuticals sector. This conservative leverage is further underpinned by a current ratio of 1.06x, signaling adequate liquidity to cover short-term obligations. However, the cash conversion cycle (CCC) of 106 days, while improved from previous periods, indicates that the company still takes a considerable amount of time to convert its investments into cash flow. This could pose risks if not monitored closely, as prolonged cash cycles can strain operational flexibility. The return on equity (ROE) at 10.8% reflects a moderate ability to generate returns for shareholders, but there is room for improvement, especially when compared to more aggressive peers in the industry.
Shareholding Pattern and Investor Confidence
The shareholding structure of SMS Lifesciences indicates a strong promoter backing, with promoters holding 71.40% of the company as of March 2025. This level of control can be a double-edged sword; while it reflects confidence from the management, it also means that public and institutional investors have limited influence. Foreign institutional investors (FIIs) hold a mere 0.03%, which raises questions about the stock’s attractiveness to global investors. The number of shareholders has been on a decline, from 8,799 in September 2022 to 7,412 as of March 2025. This trend may imply a waning interest among retail investors, possibly due to the company’s inconsistent financial performance. On the flip side, strong promoter support can provide stability, especially during turbulent market conditions. For investors, understanding this dynamic is crucial as it reflects both confidence and potential risks associated with limited external investment.
Outlook, Risks, and Final Insight
The outlook for SMS Lifesciences hinges on its ability to navigate the challenges and leverage its strengths. The company’s recovering revenue trends and improving profitability metrics provide a foundation for optimism. However, there are significant risks to consider. The volatility in net profits and the fluctuating margins could deter potential investors, especially those seeking stability. Furthermore, the prolonged cash conversion cycle raises liquidity concerns that could affect operational efficiency. Investors should also be cautious of the limited foreign institutional interest, as this could impact the stock’s liquidity and market perception. In essence, while SMS Lifesciences presents an intriguing case with its strong promoter backing and recovery in sales, the journey ahead will require vigilant management of operational efficiencies and a strategic approach to enhancing profitability. Investors would do well to keep a close eye on quarterly results and any strategic initiatives aimed at bolstering growth and operational health.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of SMS Lifesciences India Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 146 Cr. | 116 | 247/84.3 | 32.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,112 Cr. | 377 | 479/192 | 85.2 | 24.3 | 0.18 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.5 Cr. | 47.9 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 44.0 Cr. | 30.0 | 30.5/17.0 | 105 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,580.44 Cr | 1,173.08 | 51.95 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 82.28 | 81.26 | 88.29 | 63.73 | 74.65 | 69.26 | 72.05 | 89.99 | 92.55 | 78.46 | 84.60 | 89.11 | 82.50 |
| Expenses | 73.79 | 72.99 | 78.92 | 61.45 | 72.11 | 61.33 | 62.75 | 78.63 | 76.27 | 69.89 | 71.85 | 81.69 | 70.79 |
| Operating Profit | 8.49 | 8.27 | 9.37 | 2.28 | 2.54 | 7.93 | 9.30 | 11.36 | 16.28 | 8.57 | 12.75 | 7.42 | 11.71 |
| OPM % | 10.32% | 10.18% | 10.61% | 3.58% | 3.40% | 11.45% | 12.91% | 12.62% | 17.59% | 10.92% | 15.07% | 8.33% | 14.19% |
| Other Income | 0.31 | 0.15 | 0.49 | 4.81 | 0.61 | 0.27 | 0.58 | 2.36 | 0.44 | 2.04 | 0.06 | 2.34 | 1.00 |
| Interest | 1.64 | 1.68 | 1.67 | 1.80 | 2.18 | 2.81 | 2.34 | 2.84 | 2.40 | 2.14 | 2.14 | 2.03 | 1.87 |
| Depreciation | 2.59 | 2.64 | 2.63 | 2.92 | 3.70 | 3.73 | 3.73 | 3.78 | 3.68 | 3.76 | 3.76 | 3.80 | 3.82 |
| Profit before tax | 4.57 | 4.10 | 5.56 | 2.37 | -2.73 | 1.66 | 3.81 | 7.10 | 10.64 | 4.71 | 6.91 | 3.93 | 7.02 |
| Tax % | 49.23% | 23.66% | 31.29% | 10.55% | 40.29% | 126.51% | -8.14% | 8.73% | 33.27% | 29.72% | 29.81% | 11.45% | 37.61% |
| Net Profit | 2.32 | 3.12 | 3.82 | 2.11 | -3.83 | -0.44 | 4.12 | 6.47 | 7.10 | 3.30 | 4.86 | 3.48 | 4.39 |
| EPS in Rs | 9.96 | 9.10 | 13.20 | 5.66 | -5.95 | 2.25 | 14.22 | 19.52 | 23.15 | 15.45 | 18.09 | 9.82 | 13.76 |
Last Updated: August 20, 2025, 3:25 am
Below is a detailed analysis of the quarterly data for SMS Lifesciences India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 82.50 Cr.. The value appears to be declining and may need further review. It has decreased from 89.11 Cr. (Mar 2025) to 82.50 Cr., marking a decrease of 6.61 Cr..
- For Expenses, as of Jun 2025, the value is 70.79 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 81.69 Cr. (Mar 2025) to 70.79 Cr., marking a decrease of 10.90 Cr..
- For Operating Profit, as of Jun 2025, the value is 11.71 Cr.. The value appears strong and on an upward trend. It has increased from 7.42 Cr. (Mar 2025) to 11.71 Cr., marking an increase of 4.29 Cr..
- For OPM %, as of Jun 2025, the value is 14.19%. The value appears strong and on an upward trend. It has increased from 8.33% (Mar 2025) to 14.19%, marking an increase of 5.86%.
- For Other Income, as of Jun 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.34 Cr. (Mar 2025) to 1.00 Cr., marking a decrease of 1.34 Cr..
- For Interest, as of Jun 2025, the value is 1.87 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.03 Cr. (Mar 2025) to 1.87 Cr., marking a decrease of 0.16 Cr..
- For Depreciation, as of Jun 2025, the value is 3.82 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.80 Cr. (Mar 2025) to 3.82 Cr., marking an increase of 0.02 Cr..
- For Profit before tax, as of Jun 2025, the value is 7.02 Cr.. The value appears strong and on an upward trend. It has increased from 3.93 Cr. (Mar 2025) to 7.02 Cr., marking an increase of 3.09 Cr..
- For Tax %, as of Jun 2025, the value is 37.61%. The value appears to be increasing, which may not be favorable. It has increased from 11.45% (Mar 2025) to 37.61%, marking an increase of 26.16%.
- For Net Profit, as of Jun 2025, the value is 4.39 Cr.. The value appears strong and on an upward trend. It has increased from 3.48 Cr. (Mar 2025) to 4.39 Cr., marking an increase of 0.91 Cr..
- For EPS in Rs, as of Jun 2025, the value is 13.76. The value appears strong and on an upward trend. It has increased from 9.82 (Mar 2025) to 13.76, marking an increase of 3.94.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:25 am
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 378 | 261 | 266 | 350 | 316 | 306 | 345 | 335 |
| Expenses | 343 | 235 | 235 | 316 | 287 | 275 | 300 | 294 |
| Operating Profit | 35 | 25 | 30 | 35 | 29 | 31 | 45 | 40 |
| OPM % | 9% | 10% | 11% | 10% | 9% | 10% | 13% | 12% |
| Other Income | 2 | 2 | 2 | 14 | 5 | 4 | 5 | 5 |
| Interest | 6 | 5 | 5 | 6 | 7 | 10 | 9 | 8 |
| Depreciation | 6 | 8 | 8 | 10 | 11 | 15 | 15 | 15 |
| Profit before tax | 25 | 15 | 20 | 33 | 17 | 10 | 26 | 23 |
| Tax % | 30% | 31% | 31% | 23% | 31% | 36% | 28% | |
| Net Profit | 18 | 10 | 14 | 25 | 11 | 6 | 19 | 16 |
| EPS in Rs | 59.04 | 33.67 | 44.85 | 83.75 | 37.91 | 30.07 | 66.52 | 57.12 |
| Dividend Payout % | 3% | 0% | 3% | 2% | 4% | 5% | 2% |
YoY Net Profit Growth
| Year | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -44.44% | 40.00% | 78.57% | -56.00% | -45.45% | 216.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | 84.44% | 38.57% | -134.57% | 10.55% | 262.12% |
SMS Lifesciences India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2019-2020 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | -1% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 15% |
| 3 Years: | 8% |
| TTM: | -3% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 20% |
| 3 Years: | 17% |
| 1 Year: | -30% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 9% |
| 3 Years: | 8% |
| Last Year: | 11% |
Last Updated: September 5, 2025, 1:31 pm
Balance Sheet
Last Updated: October 10, 2025, 2:59 pm
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | 103 | 113 | 126 | 149 | 166 | 174 | 194 |
| Borrowings | 47 | 65 | 65 | 80 | 100 | 101 | 86 |
| Other Liabilities | 116 | 72 | 108 | 125 | 126 | 114 | 107 |
| Total Liabilities | 270 | 253 | 302 | 357 | 395 | 391 | 390 |
| Fixed Assets | 118 | 124 | 130 | 142 | 228 | 223 | 232 |
| CWIP | 3 | 16 | 38 | 51 | 1 | 6 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 148 | 113 | 134 | 164 | 166 | 162 | 158 |
| Total Assets | 270 | 253 | 302 | 357 | 395 | 391 | 390 |
Below is a detailed analysis of the balance sheet data for SMS Lifesciences India Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 3.00 Cr..
- For Reserves, as of Mar 2025, the value is 194.00 Cr.. The value appears strong and on an upward trend. It has increased from 174.00 Cr. (Mar 2024) to 194.00 Cr., marking an increase of 20.00 Cr..
- For Borrowings, as of Mar 2025, the value is 86.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 101.00 Cr. (Mar 2024) to 86.00 Cr., marking a decrease of 15.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 107.00 Cr.. The value appears to be improving (decreasing). It has decreased from 114.00 Cr. (Mar 2024) to 107.00 Cr., marking a decrease of 7.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 390.00 Cr.. The value appears to be improving (decreasing). It has decreased from 391.00 Cr. (Mar 2024) to 390.00 Cr., marking a decrease of 1.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 232.00 Cr.. The value appears strong and on an upward trend. It has increased from 223.00 Cr. (Mar 2024) to 232.00 Cr., marking an increase of 9.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 6.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 6.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 158.00 Cr.. The value appears to be declining and may need further review. It has decreased from 162.00 Cr. (Mar 2024) to 158.00 Cr., marking a decrease of 4.00 Cr..
- For Total Assets, as of Mar 2025, the value is 390.00 Cr.. The value appears to be declining and may need further review. It has decreased from 391.00 Cr. (Mar 2024) to 390.00 Cr., marking a decrease of 1.00 Cr..
Notably, the Reserves (194.00 Cr.) exceed the Borrowings (86.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Free Cash Flow | -12.00 | -40.00 | -35.00 | -45.00 | -71.00 | -70.00 | -41.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 40 | 30 | 47 | 35 | 53 | 61 | 73 |
| Inventory Days | 116 | 149 | 164 | 159 | 184 | 196 | 160 |
| Days Payable | 140 | 101 | 163 | 146 | 127 | 143 | 126 |
| Cash Conversion Cycle | 16 | 78 | 48 | 48 | 110 | 115 | 106 |
| Working Capital Days | 14 | 18 | 2 | 17 | 24 | 11 | 7 |
| ROCE % | 12% | 13% | 12% | 8% | 7% | 12% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 66.51 | 30.08 | 37.92 | 83.61 | 44.84 |
| Diluted EPS (Rs.) | 66.51 | 30.08 | 37.92 | 83.61 | 44.84 |
| Cash EPS (Rs.) | 111.56 | 70.34 | 73.32 | 116.78 | 70.84 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 650.15 | 640.48 | 622.55 | 545.53 | 427.40 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 650.15 | 640.48 | 622.55 | 545.53 | 427.40 |
| Revenue From Operations / Share (Rs.) | 1140.22 | 1012.00 | 1043.76 | 1156.83 | 878.48 |
| PBDIT / Share (Rs.) | 165.05 | 115.57 | 105.27 | 119.80 | 105.71 |
| PBIT / Share (Rs.) | 115.44 | 66.16 | 69.58 | 86.70 | 79.70 |
| PBT / Share (Rs.) | 86.63 | 32.57 | 54.88 | 108.26 | 64.72 |
| Net Profit / Share (Rs.) | 61.96 | 20.93 | 37.63 | 83.68 | 44.84 |
| NP After MI And SOA / Share (Rs.) | 66.51 | 30.07 | 37.91 | 83.76 | 44.84 |
| PBDIT Margin (%) | 14.47 | 11.42 | 10.08 | 10.35 | 12.03 |
| PBIT Margin (%) | 10.12 | 6.53 | 6.66 | 7.49 | 9.07 |
| PBT Margin (%) | 7.59 | 3.21 | 5.25 | 9.35 | 7.36 |
| Net Profit Margin (%) | 5.43 | 2.06 | 3.60 | 7.23 | 5.10 |
| NP After MI And SOA Margin (%) | 5.83 | 2.97 | 3.63 | 7.24 | 5.10 |
| Return on Networth / Equity (%) | 10.23 | 5.14 | 6.79 | 16.63 | 10.49 |
| Return on Capital Employeed (%) | 14.07 | 8.13 | 8.04 | 11.84 | 12.77 |
| Return On Assets (%) | 5.15 | 2.32 | 2.90 | 7.09 | 4.48 |
| Long Term Debt / Equity (X) | 0.09 | 0.18 | 0.32 | 0.26 | 0.30 |
| Total Debt / Equity (X) | 0.42 | 0.55 | 0.58 | 0.50 | 0.45 |
| Asset Turnover Ratio (%) | 0.88 | 0.77 | 0.83 | 1.13 | 0.99 |
| Current Ratio (X) | 1.06 | 1.07 | 1.19 | 1.15 | 1.11 |
| Quick Ratio (X) | 0.58 | 0.51 | 0.54 | 0.52 | 0.56 |
| Inventory Turnover Ratio (X) | 2.02 | 1.79 | 2.00 | 3.02 | 2.24 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 4.98 | 3.95 | 1.79 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 1.88 | 2.03 | 1.28 | 0.00 |
| Earning Retention Ratio (%) | 0.00 | 95.02 | 96.05 | 98.21 | 0.00 |
| Cash Earning Retention Ratio (%) | 0.00 | 98.12 | 97.97 | 98.72 | 0.00 |
| Interest Coverage Ratio (X) | 5.73 | 3.44 | 4.68 | 5.87 | 7.06 |
| Interest Coverage Ratio (Post Tax) (X) | 3.15 | 1.62 | 2.33 | 3.04 | 3.99 |
| Enterprise Value (Cr.) | 424.63 | 318.25 | 271.04 | 295.69 | 197.88 |
| EV / Net Operating Revenue (X) | 1.23 | 1.04 | 0.85 | 0.84 | 0.74 |
| EV / EBITDA (X) | 8.51 | 9.11 | 8.52 | 8.16 | 6.19 |
| MarketCap / Net Operating Revenue (X) | 0.94 | 0.67 | 0.49 | 0.60 | 0.56 |
| Retention Ratios (%) | 0.00 | 95.01 | 96.04 | 98.20 | 0.00 |
| Price / BV (X) | 1.66 | 1.16 | 0.93 | 1.38 | 1.16 |
| Price / Net Operating Revenue (X) | 0.94 | 0.67 | 0.49 | 0.60 | 0.56 |
| EarningsYield | 0.06 | 0.04 | 0.07 | 0.12 | 0.09 |
After reviewing the key financial ratios for SMS Lifesciences India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 66.51. This value is within the healthy range. It has increased from 30.08 (Mar 24) to 66.51, marking an increase of 36.43.
- For Diluted EPS (Rs.), as of Mar 25, the value is 66.51. This value is within the healthy range. It has increased from 30.08 (Mar 24) to 66.51, marking an increase of 36.43.
- For Cash EPS (Rs.), as of Mar 25, the value is 111.56. This value is within the healthy range. It has increased from 70.34 (Mar 24) to 111.56, marking an increase of 41.22.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 650.15. It has increased from 640.48 (Mar 24) to 650.15, marking an increase of 9.67.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 650.15. It has increased from 640.48 (Mar 24) to 650.15, marking an increase of 9.67.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,140.22. It has increased from 1,012.00 (Mar 24) to 1,140.22, marking an increase of 128.22.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 165.05. This value is within the healthy range. It has increased from 115.57 (Mar 24) to 165.05, marking an increase of 49.48.
- For PBIT / Share (Rs.), as of Mar 25, the value is 115.44. This value is within the healthy range. It has increased from 66.16 (Mar 24) to 115.44, marking an increase of 49.28.
- For PBT / Share (Rs.), as of Mar 25, the value is 86.63. This value is within the healthy range. It has increased from 32.57 (Mar 24) to 86.63, marking an increase of 54.06.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 61.96. This value is within the healthy range. It has increased from 20.93 (Mar 24) to 61.96, marking an increase of 41.03.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 66.51. This value is within the healthy range. It has increased from 30.07 (Mar 24) to 66.51, marking an increase of 36.44.
- For PBDIT Margin (%), as of Mar 25, the value is 14.47. This value is within the healthy range. It has increased from 11.42 (Mar 24) to 14.47, marking an increase of 3.05.
- For PBIT Margin (%), as of Mar 25, the value is 10.12. This value is within the healthy range. It has increased from 6.53 (Mar 24) to 10.12, marking an increase of 3.59.
- For PBT Margin (%), as of Mar 25, the value is 7.59. This value is below the healthy minimum of 10. It has increased from 3.21 (Mar 24) to 7.59, marking an increase of 4.38.
- For Net Profit Margin (%), as of Mar 25, the value is 5.43. This value is within the healthy range. It has increased from 2.06 (Mar 24) to 5.43, marking an increase of 3.37.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 5.83. This value is below the healthy minimum of 8. It has increased from 2.97 (Mar 24) to 5.83, marking an increase of 2.86.
- For Return on Networth / Equity (%), as of Mar 25, the value is 10.23. This value is below the healthy minimum of 15. It has increased from 5.14 (Mar 24) to 10.23, marking an increase of 5.09.
- For Return on Capital Employeed (%), as of Mar 25, the value is 14.07. This value is within the healthy range. It has increased from 8.13 (Mar 24) to 14.07, marking an increase of 5.94.
- For Return On Assets (%), as of Mar 25, the value is 5.15. This value is within the healthy range. It has increased from 2.32 (Mar 24) to 5.15, marking an increase of 2.83.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 0.2. It has decreased from 0.18 (Mar 24) to 0.09, marking a decrease of 0.09.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.42. This value is within the healthy range. It has decreased from 0.55 (Mar 24) to 0.42, marking a decrease of 0.13.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.88. It has increased from 0.77 (Mar 24) to 0.88, marking an increase of 0.11.
- For Current Ratio (X), as of Mar 25, the value is 1.06. This value is below the healthy minimum of 1.5. It has decreased from 1.07 (Mar 24) to 1.06, marking a decrease of 0.01.
- For Quick Ratio (X), as of Mar 25, the value is 0.58. This value is below the healthy minimum of 1. It has increased from 0.51 (Mar 24) to 0.58, marking an increase of 0.07.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.02. This value is below the healthy minimum of 4. It has increased from 1.79 (Mar 24) to 2.02, marking an increase of 0.23.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 4.98 (Mar 24) to 0.00, marking a decrease of 4.98.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 1.88 (Mar 24) to 0.00, marking a decrease of 1.88.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 95.02 (Mar 24) to 0.00, marking a decrease of 95.02.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 98.12 (Mar 24) to 0.00, marking a decrease of 98.12.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.73. This value is within the healthy range. It has increased from 3.44 (Mar 24) to 5.73, marking an increase of 2.29.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.15. This value is within the healthy range. It has increased from 1.62 (Mar 24) to 3.15, marking an increase of 1.53.
- For Enterprise Value (Cr.), as of Mar 25, the value is 424.63. It has increased from 318.25 (Mar 24) to 424.63, marking an increase of 106.38.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.23. This value is within the healthy range. It has increased from 1.04 (Mar 24) to 1.23, marking an increase of 0.19.
- For EV / EBITDA (X), as of Mar 25, the value is 8.51. This value is within the healthy range. It has decreased from 9.11 (Mar 24) to 8.51, marking a decrease of 0.60.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.94. This value is below the healthy minimum of 1. It has increased from 0.67 (Mar 24) to 0.94, marking an increase of 0.27.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 95.01 (Mar 24) to 0.00, marking a decrease of 95.01.
- For Price / BV (X), as of Mar 25, the value is 1.66. This value is within the healthy range. It has increased from 1.16 (Mar 24) to 1.66, marking an increase of 0.50.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.94. This value is below the healthy minimum of 1. It has increased from 0.67 (Mar 24) to 0.94, marking an increase of 0.27.
- For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has increased from 0.04 (Mar 24) to 0.06, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in SMS Lifesciences India Ltd:
- Net Profit Margin: 5.43%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 14.07% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 10.23% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.15
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.58
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 20.6 (Industry average Stock P/E: 51.95)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.42
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 5.43%
About the Company
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Plot No.19-III, Road No.71, Hyderabad Telangana 500096 | info@smslife.in http://www.smslife.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. TVVSN Murthy | Managing Director |
| Mr. T V Praveen | Executive Director |
| Mrs. Sudeepthi Gopineedi | Whole Time Director |
| Mr. P Sarath Kumar | Independent Director |
| Dr. Srinivas Samavedam | Independent Director |
| Dr. Mannam Malakondaiah | Independent Director |
SMS Lifesciences India Ltd. Share Price Update | |
|---|---|
| Share Price | Value |
| Today | ₹660.60 |
| Previous Day | ₹657.35 |
FAQ
What is the intrinsic value of SMS Lifesciences India Ltd?
SMS Lifesciences India Ltd's intrinsic value (as of 08 December 2025) is 1158.40 which is 3.22% lower the current market price of 1,197.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 357 Cr. market cap, FY2025-2026 high/low of 1,680/956, reserves of ₹194 Cr, and liabilities of 390 Cr.
What is the Market Cap of SMS Lifesciences India Ltd?
The Market Cap of SMS Lifesciences India Ltd is 357 Cr..
What is the current Stock Price of SMS Lifesciences India Ltd as on 08 December 2025?
The current stock price of SMS Lifesciences India Ltd as on 08 December 2025 is 1,197.
What is the High / Low of SMS Lifesciences India Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of SMS Lifesciences India Ltd stocks is 1,680/956.
What is the Stock P/E of SMS Lifesciences India Ltd?
The Stock P/E of SMS Lifesciences India Ltd is 20.6.
What is the Book Value of SMS Lifesciences India Ltd?
The Book Value of SMS Lifesciences India Ltd is 650.
What is the Dividend Yield of SMS Lifesciences India Ltd?
The Dividend Yield of SMS Lifesciences India Ltd is 0.13 %.
What is the ROCE of SMS Lifesciences India Ltd?
The ROCE of SMS Lifesciences India Ltd is 11.8 %.
What is the ROE of SMS Lifesciences India Ltd?
The ROE of SMS Lifesciences India Ltd is 10.8 %.
What is the Face Value of SMS Lifesciences India Ltd?
The Face Value of SMS Lifesciences India Ltd is 10.0.